Co-enzyme Q10 and idebenone use in Friedreich's ataxia

Journal of Neurochemistry

Volumn 126, Issue SUPPL.1, 2013, Pages 125-141

  Parkinson, Michael H ^a   Schulz, Jörg B ^b   Giunti, Paola ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF AACHEN MEDICAL CENTER   (Germany)

Author keywords

clinical trials; co enzyme Q10; Friedreich's ataxia; idebenone

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CREATINE PHOSPHATE; DEFERIPRONE; DIHYDROOROTATE DEHYDROGENASE; IDEBENONE; LIPOPROTEIN; PLACEBO; PYRIMIDINE; UBIDECARENONE; ANTIOXIDANT; DRUG DERIVATIVE; UBIQUINONE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD DYSCRASIA; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPEPSIA; FRIEDREICH ATAXIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LOOSE FECES; LOW DRUG DOSE; MITOCHONDRIAL MEMBRANE POTENTIAL; NAUSEA; NEUTROPENIA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PYRIMIDINE SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STRUCTURE ANALYSIS; THORAX PAIN; VOMITING; CLINICAL TRIAL (TOPIC); CO-ENZYME Q10;

CLINICAL TRIALS; CO-ENZYME Q10; FRIEDREICH'S ATAXIA; IDEBENONE;

ANTIOXIDANTS; FRIEDREICH ATAXIA; HUMANS; UBIQUINONE;

EID: 84880345042     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12322     Document Type: Review

References (72)

1. Arce P. M., Khdour O. M., Goldschmidt R., Armstrong J. S., and, Hecht S. M., (2011) A strategy for suppressing redox stress within mitochondria. ACS Med. Chem. Lett. 2, 608-613.
2. Arnold P., Boulat O., Mairec R, and, Kuntzer T,. (2006) Expanding view of phenotype and oxidative stress in Friedreich's ataxia patients with and without idebenone. Schweizer Archiv. Neurol. Psychiatr. 157, 169-176.
3. Artuch R., Aracil A., Mas A., Colomé C., Rissech M., Monrõs E., and, Pineda M., (2002) Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics 33, 190-193.
4. Artuch R., Aracil A., Mas A., Monrõs E., Vilaseca M. A., and, Pineda M., (2004) Cerebrospinal fluid concentrations of idebenone in Friedreich ataxia patients. Neuropediatrics 35, 95-98.
5. Bentinger M., Dallner G., Chojnacki T., and, Swiezewska E., (2003) Distribution and breakdown of lebeled coenzyme Q10 in rat. Free Radic. Biol. Med. 34, 563-575.
6. Bentinger M., Tekle M., and, Dallner G., (2010) Coenzyme Q-Biosynthesis and functions. Biochem. Biophys. Res. Commun. 396, 74-79.
7. Bhagavan H. N., and, Chopra R. K., (2006) Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic. Res. 40, 445-453.
8. Bhagavan H. N., and, Chopra R. K., (2007) Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion 7 (Suppl), S78-S88.
9. Bradley J. L., Blake J. C., Chamberlain S., Thomas P. K., Cooper J. M., and, Schapira A. H. V., (2000) Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum. Mol. Genet. 9, 275-282.
10. Brandsema J. F., Stephens D., Hartley J., and, Yoon G., (2010) Intermediate-dose idebenone and quality of life in Friedreich ataxia. Pediatr. Neurol. 42, 338-342.
11. Buyse G., Mertens L., Di Salvo G., Matthijs I., Weidemann F., Eyskens B., Goossens W., Goemans N., Sutherland G. R., and, Van Hove J. L. K., (2002) Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring. Neurology 60, 1679-1681.
12. Campuzano V., Montermini L., Dolores Moltò M., et al,. (1996) Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423-1427.
13. Campuzano V., Montermini L., Lutz Y., et al,. (1997) Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet. 6, 1771-1780.
14. 10 therapy. Eur. J. Neurol. 15, 1371-1379.
15. Delatycki M. B., Camakaris J., Brooks H., Evans-Whipp T., Thorburn D. R., Williamson R., and, Forrest S. M,. (1999) Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann. Neurol. 45, 673-675.
16. Di Prospero N. A., Baker A., Jeffries N., and, Fischbeck K. H., (2007a) Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 6, 878-886.
17. Di Prospero N. A., Sumner C. J., Penzak S. R., Ravina B., Fischbeck K. H., and, Taylor J. P., (2007b) Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch. Neurol. 64, 803-808.
18. Drinkard B. E., Keyser R. E., Paul S. M., Arena R., Plehn J. F., Yanovski J. A., and, Di Prospero N. A., (2010) Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia. Arch. Phys. Med. Rehabil. 91, 1044-1050.
19. Duberley K. E. C., Hargreaves I. P., Chaiwatanasirikul K.-A., Heales S. J. R., Land J. M., Rahman S., Mills K., and, Eaton S., (2013) Coenzyme Q10 quantification in muscle, fibroblasts and cerebrospinal fluid by liquid chromatography/tandem mass spectrometry using a novel deuterated internal standard. Rapid Commun. Mass Spectrom. 27, 924-930.
20. Dürr A., Cossée M., Agid Y., Campuzano V., Miganrd C., Penet C., Mandel J.-L., Brice A., and, Koenig M., (1996) Clinical and genetic abnormalities in patients with Friedreich's ataxia. N. Engl. J. Med. 335, 1169-1175.
21. Emond M., Lepage G., Vanasse M., and, Pandolfo M., (2000) Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology 55, 1753-1753.
22. Esposti M. D., Ngo A., Ghelli A., Benelli B., Carelli V., McLennan H., and, Linnane A. W., (1996) The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria. Arch. Biochem. Biophys. 330, 395-400.
23. Evans D. R., and, Guy H. I., (2004) Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J. Biol. Chem. 279, 33035-33038.
24. Fash D. M., Khdour O. M., Sahdeo S. J., Goldschmidt R., Jaruvangsanti J., Dey S., Arce P. M., Collin V. C., Cortopassi G. A., and, Hecht S. M., (2013) Effects of alkyl side chain modification of coenzyme Q10 on mitochondrial respiratory chain function and cytoprotection. Bioorg. Med. Chem. 21, 2346-2354.
25. Gane E. J., Weilert F., Orr D. W., Keogh G. F., Gibson M., Lockhart M. M., Frampton C. M., Taylor K. M., Smith R. A., and, Murphy M. P., (2010) The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 30, 1019-1026.
26. Giacchetti M., Monticelli A., De Biase I., Pianese L., Turano M., Filla A., De Michele G., and, Cocozza S., (2004) Mitochondrial DNA haplogroups influence the Friedreich's ataxia phenotype. J. Med. Genet. 41, 293-295.
27. Giunti P., Greenfield J., Stevenson A. J., Parkinson M. H., Hartmann J. H., Sandtmann R., Piercy J., O'Hara J., Ruiz-Casas L., and, Smith F. M,. (2013) Impact of Friedreich's ataxia on healthcare resource utilization in the United Kingdom and Germany. Orphanet J. Rare Dis. 8, 38.
28. Harding A., (1981) Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 104, 589-620.
29. Hargreaves I. P., (2003) Ubiquinone: cholesterol's reclusive cousin. Ann. Clin. Biochem. 40, 207-218.
30. Hart P. E., Lodi R., Rajagopalan B., et al,. (2005) Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch. Neurol. 62, 621-626.
31. Hausse A. O., Aggoun Y., Bonnet D., Sidi D., Munnich A., Rötig A., and, Rustin P., (2002) Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 87, 346-349.
32. Heidari M. M., Houshmand M., Hosseinkhani S., Nafissi S., Scheiber-Mojdehkar B., and, Khatam M., (2009) A novel mitochondrial heteroplasmic C13806A point mutation associated with Iranian Friedreich's ataxia. Cell. Mol. Neurobiol. 29, 225-233.
33. Houshmand M., Panahi M. S. S., Nafisi S., Soltanzadeh A., and, Alkandari F. M., (2006) Identification and sizing of GAA trinucleotide repeat expansion, investigation for D-loop variations and mitochondrial deletions in Iranian patients with Friedreich's ataxia. Mitochondrion 6, 87-93.
34. Kaikkonen J., Tuomaine T.-P., Nyyssönen K., and, Salonen J. T,. (2002) Coenzyme Q10: absorption, antioxidative properties, determinants, and plasma levels. Free Radic. Res. 36, 389-397.
35. 10 administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat. Free Radic. Biol. Med. 33, 627-638.
36. Lagedrost S. J., Sutton M. S., Cohen M. S., Satou G. M., Kaufman B. D., Perlman S. L., Rummey C., Meier T., and, Lynch D. R., (2011) Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am. Heart J. 161, 639-645.
37. Lamperti C., Naini A., Hirano M., et al,. (2003) Cerebellar ataxia and coenzyme Q10 deficiency. Neurology 60, 1206-1208.
38. Lenaz G., Fato R., Formiggini G., and, Genova M. L., (2007) The role of coenzyme Q in mitochondrial electron transport. Mitochondrion 7 (Suppl), S8-S33.
39. Lodi R., Cooper J. M., Bradley J. L., Manners D., Styles P., Taylor D. J., and, Schapira A. H. V., (1999) Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc. Natl Acad. Sci. USA 96, 11492-11495.
40. Lodi R., Hart P. E., Rajagopalan B., et al,. (2001) Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann. Neurol. 49, 590-596.
41. Lynch D. R., Perlman S. L., and, Meier T., (2010) A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch. Neurol. 67, 941-947.
42. Mariotti C., Solari A., Torta D., Marano L., Fiorentini C., and, Di Donato S., (2002) Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 60, 1676-1679.
43. Matthews R. T., Yang L., Browne S., Baik M., and, Beal M. F., (1998) Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl Acad. Sci. USA 95, 8892-8897.
44. Meier T., and, Buyse G., (2009) Idebenone: an emerging therapy for Friedreich ataxia. J. Neurol. 256 (Suppl 1), 25-30.
45. Meier T., Perlman S. L., Rummey C., Coppard N. J., and, Lynch D. R., (2012) Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J. Neurol. 259, 284-291.
46. Metz G., Coppard N., Cooper J. M., et al,. (2013) Rating disease progression of Friedreich's ataxia by the international cooperative ataxia rating scale: analysis of a 603-patient database. Brain 136, 259-268.
47. Nagai Y., Yoshida K., Narumi S., Tanayama S., and, Nagaoka A., (1989) Brain distribution of idebenone and its effect on local cerebral glucose utilization in rats. Arch. Gerontol. Geriatr. 8, 257-272.
48. Orsucci D., Mancuso M., Caldarazzo Ienco E., LoGerfo A., and, Siciliano G., (2011) Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues. Curr. Med. Chem. 18, 4053-4064.
49. Pandolfo M., and, Pastore A., (2009) The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J. Neurol. 256 (Suppl 1), 9-17.
50. Piemonte F., Pastore A., Tozzi G., Tagliacozzi D., Santorelli F. M., Carrozzo R., Casali C., Damiano M., Federici G., and, Bertini E., (2001) Glutathione in blood of patients with Friedreich's ataxia. Eur. J. Clin. Invest. 31, 1007-1011.
51. Pineda M., Arpa J., Montero R., et al,. (2008) Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur. J. Paediatr. Neurol. 12, 470-475.
52. Ribaï P., Pousset F., Tanguy M.-L., et al,. (2007) Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Arch. Neurol. 64, 558-564.
53. Rötig A., de Lonlay P., Chretien D., Foury F., Koenig M., Sidi D., Munnich A., and, Rustin P., (1997) Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet. 17, 215-217.
54. Rustin P., von Kleist-Retzow J.-C., Chantrel-Groussard K., Sidi D., Munnich A., and, Rötig A., (1999) Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 354, 477-479.
55. Rustin P., Rötig A., Munnich A., and, Sidi D., (2002) Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic. Res. 36, 467-469.
56. Rustin P., Bonnet D., Rötig A., Munnich A., and, Sidi D., (2004) Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial (letter). Neurology 62, 524-525.
57. Santhera Pharmaceuticals. (2010) Press Statement, 20 May 2010: Santhera's MICONOS Trial with Catena®/Sovrima® in Friedreich's Ataxia Misses Primary Endpoint. http://www.santhera.com/index.php?docid=212&vid=&lang= &newsdate=201005&newsid=1417424&newslang=en. [accessed on 8 February 2013].
58. Schöls L., Vorgerd M., Schillings M., Skipka G., and, Zange J., (2001) Idebenone in patients with Friedreich ataxia. Neurosci. Lett. 306, 169-172.
59. Schulz J. B., Dehmer T., Schöls L., et al,. (2000) Oxidative stress in patients with Friedreich ataxia. Neurology 55, 1719-1721.
60. Seznec H., Simon D., Monassier L., Criqui-Filipe P., Gansmuller A., Rustin P., Koenig M., and, Puccio H., (2004a) Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum. Mol. Genet. 13, 1017-1024.
61. Seznec H., Wilson W. B., and, Puccio H., (2004b) 2003 International Friedreich's ataxia research conference,14-16 February 2003, Bethesda, MD, USA. Neuromuscul. Disord. 14, 70-82.
62. Shults C. W., Beal M. F., Song D., and, Fontaine D., (2004) Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp. Neurol. 188, 491-494.
63. Smith R. A. J., and, Murphy M. P., (2010) Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann. N. Y. Acad. Sci. 1201, 96-103.
64. Smith K. M., Matson S., Matson W. R., Cormier K., Del Signore S. J., Hagerty S. W., Stack E. C., Ryu H., and, Ferrante R. J., (2006) Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim. Biophys. Acta 1762, 616-626.
65. Snow B. J., Rolfe F. L., Lockhart M. M., Frampton C. M., O'Sullivan J. D., Fung V., Smith R. A., Murphy M. P., and, Taylor K. M., (2010) A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov. Disord. 25, 1670-1674.
66. Sugiyama Y., Fujita T., Matsumoto M., Okamoto K., and, Imada I., (1985) Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs. J. Pharmacobio-dyn. 8, 1006-1017.
67. Suno M., and, Nagaoka A., (1984) Inhibition of lipid peroxidation by a novel compound, idebenone (CV-2619). Jpn. J. Pharmacol. 35, 196-200.
68. Torii H., Yoshida K., Kobayashi T., Tsukamoto T., and, Tanayama S., (1985) Disposition of idebenone (CV-2619), a new cerebral metabolism improving agent, in rats and dogs. J. Pharmacobio-dyn. 8, 457-467.
69. Turunen M., Appelkvist E.-L., Sindelar P., and, Dallner G., (1999) Blood concentration of coenzyme Q10 increases in rats when esterified forms are administered. J. Nutr. 129, 2113-2118.
70. Velasco-Sánchez D., Aracil A., Montero R., et al,. (2011) Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 10, 1-8.
71. Weidemann F., Rummey C., Bijnens B., Stoörk S., Jasaityte R., Dhooge J., Baltabaeva A., Sutherland G., Schulz J. B., and, Meier T., (2012) The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation 125, 1626-1634.
72. Wilson R.B. Roof D.M. Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue Nat. Genet. 1997 16 352-357